Search Results - "Aveson, V."

Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility by Dhara, S., Chhangawala, S., Chintalapudi, H., Askan, G., Aveson, V., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., Melchor, J. P., Bermeo, J., Cardenas, A., Sinha, S., Glassman, D., Nicolle, R., Moffitt, R., Yu, K. H., Leppanen, S., Laderman, S., Curry, B., Gui, J., Balachandran, V. P., Iacobuzio-Donahue, C., Chandwani, R., Leslie, C. S., Leach, S. D.

“…Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of…”
Get full text

Association Between Biopsy Method and Development of Peritoneal Metastases in Perihilar Cholangiocarcinoma by Aveson, V., Ilagan, C., Chou, J., Gönen, M., Balachandran, V., Drebin, J., Jarnagin, W., Wei, A., Kingham, T.P., D’Angelica, M.

Get full text

Association between biopsy method and development of peritoneal metastases in perihilar cholangiocarcinoma by Aveson, V., Ilagan, C.H., Chou, J., Gönen, M., Balachandran, V., Drebin, J., Jarnagin, W., Wei, A., Kingham, T.P., D'Angelica, M.

Get full text

Distinct KRAS Mutations are Enriched in Early-Stage Resected Pancreatic Ductal Adenocarcinoma by McIntyre, C., Grimont, A., Aveson, V., Seier, K., Walch, H., Pulvirenti, A., Gelfer, R., Gonen, M., Schultz, N., Park, W., O'Reilly, E., Jarnagin, W., Chandwani, R.

Get full text